logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10987369 B1

PDFFull Text
Date of Patent:
Apr. 27, 2021

Filed:

Apr. 09, 2015

Pdia4 protein as a target for diagnosis, monitoring and treatment of diabetes

Applicant:

Academia Sinica, Taipei, TW;

Inventors:

Wen-Chin Yang, Taichung County, TW;

Lee-Tian Chang, Taichung, TW;

Assignee:

ACADEMIA SINICA, Taipei, TW;

Attorneys:

Hsiu-Ming Saunders

Intellectual Property

Primary Examiner:

Shaojia A Jiang

Assistant Examiner:

Michael C Henry

Int. Cl.
CPC ...
A61K 31/7028 (2006.01); A61K 38/43 (2006.01); A61K 31/7105 (2006.01); A61K 31/341 (2006.01); A61K 31/216 (2006.01); A61K 31/235 (2006.01); A61K 31/58 (2006.01); A61K 31/155 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7028 (2013.01); A61K 31/155 (2013.01); A61K 31/216 (2013.01); A61K 31/235 (2013.01); A61K 31/341 (2013.01); A61K 31/4439 (2013.01); A61K 31/58 (2013.01); A61K 31/7105 (2013.01); A61K 38/43 (2013.01); A61K 45/06 (2013.01); C12N 15/113 (2013.01); G01N 33/6893 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); G01N 2333/99 (2013.01); G01N 2500/04 (2013.01); G01N 2800/042 (2013.01);
Abstract

A Pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and/or an anti-diabetic agent.

Find Patent Forward Citations

Loading…